Journal of Virology · 1992 · 97 citations · 28 references
Life SciencesInfectious DiseasesMolecular BiologyImmunizationVaccinologyVirologyAnimal VirusesVeterinary VaccinationVeterinary VaccinesVeterinary VirologyViral StructureViral VaccinesCanine ParvovirusesCanine VirologyExperimental Animal Models Of Viral InfectionInactivated Vaccine FormulationsRecombinant Baculovirus VectorsRecombinant Viral VaccinesViral-like Particle VaccinesVirus-like Particle Immunogenicity
VP2 is the major component of canine parvovirus (CPV) capsids. The VP2-coding gene was engineered to be expressed by a recombinant baculovirus under the control of the polyhedrin promoter. A transfer vector that contains the lacZ gene under the control of the p10 promoter was used in order to facilitate the selection of recombinants. The expressed VP2 was found to be structurally and immunologically indistinguishable from authentic VP2. The recombinant VP2 shows also the capability to self-assemble, forming viruslike particles similar in size and appearance to CPV virions. These viruslike particles have been used to immunize dogs in different doses and combinations of adjuvants, and the anti-CPV responses have been measured by enzyme-linked immunosorbent assay, monolayer protection assays, and an assay for the inhibition of hemagglutination. A dose of ca. 10 micrograms of VP2 was able to elicit a good protective response, higher than that obtained with a commercially available, inactivated vaccine. The results indicate that these viruslike particles can be used to protect dogs from CPV infection.
28
Haider Raza, Annie John, Abderrahim Nemmar · Cellular Physiology and Biochemistry · 2013 · 47.3K citations · Full text
Studies on transformation of Escherichia coli with plasmids
Douglas Hanahan · Journal of Molecular Biology · 1983 · 11.3K citations
A Manual of Methods for Baculovirus Vectors and Insect Cell Culture Procedures.
Summers, Gale Smith · 1987 · 1.7K citations